Today: 30 June 2026
Robinhood stock slips again after crypto bill delay rattles traders
16 January 2026
1 min read

Robinhood stock slips again after crypto bill delay rattles traders

New York, Jan 16, 2026, 17:32 EST — After-hours

  • Robinhood shares slipped 1.4% on Friday, following a steep 7.8% plunge the day before.
  • Traders are zeroed in on a stalled U.S. Senate crypto market-structure bill following objections from Coinbase’s CEO to the draft text.
  • Upcoming milestones: new legislative text set for Jan. 21, followed by Robinhood’s results on Feb. 10.

Robinhood Markets shares closed Friday down 1.4% at $108.76, then edged up a bit in after-hours trading following a turbulent week for crypto-related stocks. The stock had dropped 7.8% on Thursday.

This matters because Robinhood is frequently seen as a barometer for retail risk appetite, especially in crypto. When Washington hesitates on crypto regulations, traders quickly adjust prices on assets linked to trading volumes, spreads, and user engagement.

Recent selling reflects renewed doubts over the Digital Asset Market Clarity Act, a much-anticipated bill aiming to establish federal guidelines for cryptocurrencies.

A U.S. Senate committee delayed its scheduled debate on the bill following comments from Coinbase CEO Brian Armstrong, who said the company couldn’t back it “in its current form,” Reuters reported. Armstrong argued, “We’d rather have no bill than a bad bill,” highlighting issues like restrictions on stablecoin rewards and worries over regulator oversight. Reuters

Senate Banking Committee Chairman Tim Scott announced in Washington that the markup is delayed as bipartisan talks carry on, emphasizing that “everyone remains at the table working in good faith.” The committee’s schedule now lists the session as postponed. Senate Banking Committee

Stablecoin jargon has turned into a hot button for investors. These tokens usually track the dollar, while so-called “rewards” often act like yield for users. Reuters flagged a clash between banks and crypto companies on whether these payouts ought to be limited or regulated as interest. Reuters

Crypto prices slipped, with bitcoin falling roughly 0.4%. Meanwhile, Coinbase shares edged up slightly late Friday.

Capitol Hill is gearing up for action: the Senate Agriculture Committee announced it will release the legislative text by the end of Jan. 21, with a committee markup scheduled for Jan. 27.

Robinhood is set to release its fourth-quarter and full-year 2025 results on Feb. 10, after the market closes. The company will hold a 5 p.m. ET call with CEO Vlad Tenev and incoming CFO Shiv Verma.

A major risk remains that the market-structure battle stretches out or the final bill emerges in a form the industry rejects, dampening sentiment toward crypto-exposed brokers and exchanges. A steeper drop in bitcoin would probably intensify that pressure.

Traders are zeroing in on the legislative text set for Jan. 21, along with any Senate Banking markup that gets rescheduled. After that, eyes will shift to Robinhood’s Feb. 10 earnings to gauge trading demand and crypto-related income.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Merck stock slips as FDA fast-track questions build and earnings near
Previous Story

Merck stock slips as FDA fast-track questions build and earnings near

Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark
Next Story

Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark

Go toTop